Thông tin thuốc gốc
Chỉ định và Liều dùng
B cell chronic lymphocytic leukaemia
Adult: As 30 mg/mL solution: Initially, 3 mg daily via infusion over 2 hours. Repeat dose daily until tolerated then increase gradually to 10 mg daily; if tolerated, start maintenance dose of 30 mg 3 times weekly given on alternate days (dose escalation usually takes 3-7 days). Total treatment duration (including dose escalation): 12 weeks. Premedicate with antihistamine and paracetamol before dosing. Administer prophylaxis for herpes virus infections and Pneumocystis jirovecii pneumonia (PCP) and continue for a minimum of 2 months after therapy. Dosing interruption or discontinuation, or infusion time extension may be required according to individual safety or tolerability (refer to detailed product guideline).

Relapsing remitting multiple sclerosis
Adult: In patients with highly active disease despite full and adequate treatment course with at least 1 disease modifying therapy, or in patients with rapidly evolving severe cases (≥2 disabling relapses in 1 year, and with ≥1 Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load compared to a previous MRI). As 12 mg/1.2 mL solution: Initial treatment course: 12 mg daily for 5 consecutive days (60 mg total dose). 2nd treatment course: 12 mg daily for 3 consecutive days (36 mg total dose), given 12 months after the initial treatment course. Up to 2 additional treatment courses may be considered as needed: 12 mg daily for 3 consecutive days (36 mg total dose), given at least 12 months after the prior treatment course. Doses are administered via infusion over 4 hours. Premedicate with corticosteroids prior to dosing. Give oral antiviral prophylaxis for herpes infections on the 1st day of each treatment course and continue for a minimum of 1 or 2 months after therapy. Dosing interruption or discontinuation, or infusion time extension may be required according to individual safety or tolerability (refer to detailed product guideline).
Hướng dẫn pha thuốc
As 30 mg/mL solution for infusion: Withdraw the appropriate dose for infusion from the vial then add into a 100 mL bag of 0.9% NaCl or 5% dextrose in water. As 12 mg/1.2 mL solution for infusion: Withdraw 1.2 mL from the vial and add into 100 mL bag of 0.9% NaCl or 5% glucose solution for infusion. Mix bag by gentle inversion.
Chống chỉ định
As 12 mg/1.2 mL solution used in relapsing-remitting multiple sclerosis (RRMS): HIV infection, severe active infection (until complete resolution), other autoimmune diseases, coagulopathy, uncontrolled hypertension; history of stroke, angina pectoris, MI or arterial dissection of the cervicocephalic arteries. Concurrent antiplatelet or anticoagulant therapy.
Thận trọng
Patient with hepatitis B or C; latent TB, pre-existing or ongoing malignancies. Concomitant administration with live vaccines. Not recommended for use in multiple sclerosis (MS) patients with inactive disease or those who are stable on other treatment. Treatment guidelines may vary among individual products (refer to product-specific recommendations). Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hepatic injury, including acute liver failure; malignancies (e.g. thyroid cancer, melanoma, lymphoproliferative disorders, lymphoma), pneumonitis, emesis, suicidal ideation; CHF, cardiomyopathy, decreased ejection fraction, severe bleeding reactions; other infections (e.g. cervical HPV infection, nasopharyngitis, upper respiratory tract infection, pneumonia, sinusitis, herpes viral infections, influenza, bronchitis, appendicitis, gastroenteritis, tooth infection, UTI, oral or vaginal candidiasis).
Blood and lymphatic system disorders: Lymphadenopathy, leukocytosis, leucopenia.
Cardiac disorders: Tachycardia, bradycardia, palpitations, chest pain or discomfort.
Ear and labyrinth disorders: Ear infection, vertigo.
Eye disorders: Conjunctivitis, endocrine ophthalmopathy, blurred vision.
Gastrointestinal disorders: Abdominal pain, nausea, diarrhoea, dyspepsia, oropharyngeal pain, dysgeusia, stomatitis.
General disorders and administration site conditions: Pyrexia, fatigue, peripheral oedema, asthenia, influenza-like illness, malaise, infusion site pain.
Immune system disorders: Cytokine release syndrome.
Injury, poisoning and procedural complications: Contusion.
Investigations: Decreased haematocrit, increased AST/ALT, increased blood creatinine.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, chills, muscle weakness, back or neck pain, pain in extremity, muscle spasms, musculoskeletal pain.
Nervous system disorders: Headache, dizziness, hypoaesthesia, paraesthesia, tremor, migraine, MS relapse.
Psychiatric disorders: Anxiety, depression, insomnia.
Renal and urinary disorders: Haematuria, proteinuria.
Reproductive system and breast disorders: Menorrhagia, irregular menstruation.
Respiratory, thoracic and mediastinal disorders: Lower respiratory tract infections, epistaxis, hiccups, cough, asthma, dyspnoea.
Skin and subcutaneous tissue disorders: Urticaria, rash, pruritus, erythema, ecchymosis, alopecia, hyperhidrosis, acne, skin lesion, dermatitis.
Vascular disorders: Flushing, hypotension or hypertension.
Potentially Fatal: Autoimmune conditions [e.g. immune thrombocytopenic purpura (ITP), haemolytic anaemia, thrombocytopenia, bone marrow hypoplasia, neutropenia, pancytopenia, lymphopenia, thyroid disorders, glomerular nephropathies including anti-glomerular basement membrane (anti-GBM) disease, autoimmune hepatitis (AIH), acquired haemophilia A], haemophagocytic lymphohistiocytosis (HLH), progressive multifocal leukoencephalopathy (PML), acute acalculous cholecystitis; ischaemic or haemorrhagic stroke, cervicocephalic arterial dissection, serious infusion-related reactions (e.g. syncope, pulmonary infiltrates, pulmonary alveolar haemorrhage, acute respiratory distress syndrome, respiratory arrest, cardiac arrhythmias, MI, myocardial ischaemia, pericarditis, acute cardiac insufficiency, cardiac arrest, anaphylaxis, angioedema, anaphylactic shock); serious bacterial (e.g. TB, listeriosis/listeria meningitis), viral [e.g. varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation], fungal and protozoan infections; severe EBV-associated hepatitis.
Chỉ số theo dõi
Monitor patients closely for signs of infection, infusion-related reactions, vital signs, depression, and suicidal behaviour or ideation. For RRMS: Obtain CBC with differential, serum creatinine, urinalysis with urine cell counts, serum ALT/AST, and total bilirubin prior to treatment initiation and monthly thereafter until ≥48 months after the last infusion; thyroid function test before initiation and every 3 months thereafter until 48 months after the last infusion. Perform skin exams at baseline then yearly for melanoma; TB screening according to local guidelines; human papilloma virus (HPV) screening annually in females. Evaluate patient for history of varicella or vaccination for VZV; if none, test for VZV antibodies and consider vaccinations for antibody-negative patients; complete necessary immunisations at least 6 weeks prior to treatment initiation. For B-CLL: Monitor CBC with differential and platelets weekly or as clinically indicated; CD4+ lymphocyte counts following treatment until recovery; CMV antigen during and for at least 2 months after therapy.
Quá liều
Symptoms: As 30 mg/mL solution used in B-cell chronic lymphocytic leukaemia (B-CLL): Bone marrow aplasia, infections or severe infusion-related reactions; acute bronchospasm, cough, and dyspnoea may occur. As 12 mg/1.2 mL solution used in RRMS: Headache, rash, hypotension or sinus tachycardia. Management: Supportive treatment.
Tương tác
Increased risk of immunosuppression with concurrent antineoplastic or immunosuppressive therapies.
Potentially Fatal: May enhance the effects of anticoagulant or antiplatelet therapy. May diminish the effects of live vaccines.
Ảnh hưởng đến kết quả xét nghiệm
May interfere with diagnostic serum tests that utilise antibodies.
Tác dụng
Description: Alemtuzumab is a recombinant humanised monoclonal antibody that binds to CD52, a nonmodulating cell-surface antigen found on B and T lymphocytes, a majority of monocytes, macrophages, natural killer (NK) cells and a subpopulation of granulocytes. The binding to CD52+ cells results in an antibody-dependent malignant cell lysis. It produces immunomodulatory effects through lymphocyte depletion and repopulation, including alteration in the proportions, number, and properties of some subsets after the treatment in MS.
Distribution: Mainly distributed into the blood and interstitial space. Volume of distribution: 0.18 L/kg (30 mg/mL solution); 14.1 L (12 mg/mL solution).
Excretion: Elimination half-life: 30 mg/mL solution: Approx 11 hours (after 1st 30 mg dose); 6 days (after the last 30 mg dose); 12 mg/1.2 mL solution: Approx 2 weeks.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Phân loại MIMS
Liệu pháp nhắm trúng đích
Phân loại ATC
L04AA34 - alemtuzumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Tài liệu tham khảo
Anon. Alemtuzumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 24/07/2020.

Buckingham R (ed). Alemtuzumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 24/07/2020.

Campath Injection (Genzyme Corporation). DailyMed. Source: U.S. National Library of Medicine. Accessed 24/07/2020.

Lemtrada 12 mg Concentrate for Solution for Infusion (Sanofi Belgium). European Medicines Agency [online]. Accessed 24/07/2020.

Lemtrada Injection, Solution, Concentrate (Genzyme Corporation). DailyMed. Source: U.S. National Library of Medicine. Accessed 24/07/2020.

Sanofi-Aventis New Zealand Limited. Lemtrada, Concentrate for Infusion 10 mg/mL data sheet 31 January 2020. Medsafe. Accessed 24/07/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Alemtuzumab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in